See more : Visium Technologies, Inc. (VISM) Income Statement Analysis – Financial Results
Complete financial analysis of Medikit Co.,Ltd. (7749.T) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Medikit Co.,Ltd., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- PT Asia Sejahtera Mina Tbk (AGAR.JK) Income Statement Analysis – Financial Results
- CST Group Limited (0985.HK) Income Statement Analysis – Financial Results
- GP-Act III Acquisition Corp. Class A Ordinary Share (GPAT) Income Statement Analysis – Financial Results
- Hellenic Telecommunications Organization S.A. (HLTOY) Income Statement Analysis – Financial Results
- Grosvenor Capital Management, L.P. (GCMG) Income Statement Analysis – Financial Results
Medikit Co.,Ltd. (7749.T)
About Medikit Co.,Ltd.
Medikit Co.,Ltd. engages in the manufacture and sale of vascular access medical devices. The company offers IV catheters, such as Supercath 5, Supercath Z3V, and Supercath Ztu-V; hemodialysis products, including Supercath PRO, Supercath NEO, and Supercath Clampcath; and intervention products comprising Supersheath and Mongoose. Its products are used in anesthetic departments, operating theaters, ICUs, and dialysis and cardiology units. The company markets its products through distributors in approximately 20 countries and territories in the European Union and on the American continent. Medikit Co.,Ltd. was founded in 1973 and is headquartered in Tokyo, Japan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 21.85B | 21.61B | 20.13B | 19.31B | 19.89B |
| Cost of Revenue | 13.10B | 13.29B | 11.95B | 11.72B | 11.81B |
| Gross Profit | 8.75B | 8.32B | 8.18B | 7.59B | 8.08B |
| Gross Profit Ratio | 40.06% | 38.50% | 40.64% | 39.31% | 40.64% |
| Research & Development | 278.00M | 323.00M | 327.00M | 357.00M | 218.54M |
| General & Administrative | 3.25B | 3.46B | 3.09B | 3.17B | 3.29B |
| Selling & Marketing | 493.00M | 470.00M | 436.00M | 420.00M | 476.00M |
| SG&A | 3.75B | 3.93B | 3.53B | 3.59B | 3.54B |
| Other Expenses | 50.00M | 70.17M | 84.53M | 56.52M | 0.00 |
| Operating Expenses | 4.07B | 4.20B | 3.76B | 3.81B | 3.76B |
| Cost & Expenses | 17.17B | 17.49B | 15.71B | 15.53B | 15.57B |
| Interest Income | 4.39M | 3.38M | 2.72M | 3.34M | 16.00M |
| Interest Expense | 7.62M | 7.55M | 7.36M | 7.19M | 7.42M |
| Depreciation & Amortization | 1.54B | 1.32B | 1.27B | 1.31B | 1.32B |
| EBITDA | 6.32B | 5.50B | 5.75B | 5.24B | 5.65B |
| EBITDA Ratio | 28.92% | 25.46% | 28.77% | 26.74% | 28.36% |
| Operating Income | 4.68B | 4.12B | 4.42B | 3.78B | 4.32B |
| Operating Income Ratio | 21.41% | 19.06% | 21.97% | 19.57% | 21.73% |
| Total Other Income/Expenses | 97.33M | 173.15M | 50.03M | 150.13M | 11.61M |
| Income Before Tax | 4.78B | 4.29B | 4.47B | 3.93B | 4.33B |
| Income Before Tax Ratio | 21.85% | 19.86% | 22.22% | 20.34% | 21.79% |
| Income Tax Expense | 1.71B | 1.43B | 1.48B | 1.27B | 1.45B |
| Net Income | 3.07B | 2.86B | 2.99B | 2.66B | 2.89B |
| Net Income Ratio | 14.05% | 13.26% | 14.87% | 13.77% | 14.52% |
| EPS | 187.95 | 170.67 | 178.14 | 157.36 | 170.33 |
| EPS Diluted | 187.95 | 170.67 | 178.14 | 157.36 | 170.33 |
| Weighted Avg Shares Out | 16.33M | 16.78M | 16.80M | 16.90M | 16.96M |
| Weighted Avg Shares Out (Dil) | 16.33M | 16.78M | 16.80M | 16.90M | 16.96M |
Source: https://incomestatements.info
Category: Stock Reports